Straits Times Index
3,394.21 +17.02 (+0.50%) S&P 500
4,070.56 +10.13 (+0.25%) Dow
33,978.08 +28.68 (+0.08%) Nasdaq
11,621.71 +109.31 (+0.95%) BTC-USD
23,773.19 +758.78 (+3.30%) CMC Crypto 200
526.66 +9.65 (+1.87%)
Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 3.0900 |
| Open | 3.0300 |
| Bid | 2.7500 x 1000 |
| Ask | 3.0200 x 2200 |
| Day's range | 2.8600 - 3.1375 |
| 52-week range | 0.9550 - 3.3800 |
| Volume | |
| Avg. volume | 1,467,268 |
| Market cap | 69.031M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8860 |
| Earnings date | 13 Mar 2023 - 17 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.29 |
- Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
SOUTH SAN FRANCISCO, Calif., January 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).
- Business Wire
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
SOUTH SAN FRANCISCO, Calif. & TOKYO, January 05, 2023--Spruce Biosciences & Kaken Pharmaceutical Announce Strategic Partnership & Exclusive Licensing Agreement to Develop Tildacerfont for CAH in Japan
- Business Wire
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
SAN FRANCISCO, November 10, 2022--Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
